Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the proquad market grown in recent years?

In the past few years, the market size for Proquad has seen a XX (HCAGR) boom. Predictions show the growth from $XX million in 2024, scaling up to $XX million in 2025 with a Compound Annual Growth Rate (CAGR) of XX%. This progress in the historic period is associated with structured immunization timelines, the benefits of combination vaccines, vaccination schemes aided by the government, outbreaks of epidemics, a robust healthcare system, and regulatory endorsements.

How is the proquad market size expected to evolve during the forecast period?

In the coming years, the proquad market is projected to witness a compound annual growth rate (CAGR) of XX%, raising its value to $XX million by 2029. The anticipated growth during the forecast period is largely driven by increasing population, better access to healthcare services, worldwide health initiatives, heightened recognition of diseases that can be prevented through vaccination, governmental funding for vaccination, and a heightened emphasis on preventive healthcare. The forecast period is characterized by trends such as global vaccine coverage, advancements in vaccine delivery technology, the inclusion of vaccines in ordinary health regimes, an enhancement in vaccine accessibility, and a rise in vaccine safety awareness.

Get your proquad market report here!

https://www.thebusinessresearchcompany.com/report/proquad-global-market-report

Which key drivers are propelling the proquad market’s growth?

The escalating rates of measles and chickenpox are projected to boost the expansion of the proquad market. Measles is mostly represented by symptoms like high fever, cough, and red rash, and this extremely infectious disease can be avoided with immunization. Similarly, chickenpox, an infectious disease that results in itchy blister-like rashes, can also be prevented by vaccination and is caused by the Varicella-zoster virus. Lower vaccination rates, misconceptions about vaccines, increased international travel, and outbreaks among unvaccinated groups, have led to a surge in cases of these otherwise preventable diseases. Proquad offers an effective solution with a combination vaccine for measles, mumps, rubella, and chickenpox (varicella), which offers protection from these conditions through a single dose, lessening the likelihood of infection, managing outbreaks, and providing well-rounded coverage to prevent complications relating to measles and chickenpox. For example, as per the World Health Organization, a non-profit organization based in Switzerland, 56,634 cases of measles were officially recorded across 45 out of 53 countries within the WHO European Region during the first three months of 2024 along with four fatalities. Over 2023, there were 61,070 cases and 13 deaths reported across 41 countries. Consequently, the elevated incidence of measles and chickenpox is stimulating the growth of the proquad market.

What are the market segments in the proquad industry?

The proquad market covered in this report is segmented –

1) By Indication: Measles; Mumps; Rubella; Varicella

2) By Patient Type: Pediatric Patient; Adult Patient

3) By End User: Healthcare Providers; Pharmacies; Public Health Organization

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20349&type=smp

Which leading companies are shaping the growth of the proquad market?

Major companies operating in the proquad market are Merck and Co. Inc.

What key trends are currently impacting the proquad market’s development?

The proquad market is trending towards enlarging the range of vaccine administration methods, with a focus on intramuscular (IM) injections, in order to advance both convenience and uniformity in immunization protocols. IM administration is a method that injects vaccines or medications directly into the muscle tissue for quicker absorption into the bloodstream. For example, in March 2023, the U.S. based pharmaceutical firm, Merck & Co. Inc., was greenlighted by the U.S. Food and Drug Administration (FDA) to include an IM administration option in the U.S. Product Insert (USPI) for its MMRV vaccine lineup, which includes ProQuad. This authorization means that the MMRV vaccine lineup now aligns with other frequently recommended vaccines that are administered intramuscularly. U.S. healthcare professionals can now opt to administer all conventionally recommended injectable pediatric vaccines in the CDC immunization schedule through the same IM method. The trio of M-M-R II, VARIVAX, and ProQuad are the only authorized IM vaccines for measles, mumps, rubella, and varicella in the U.S. The MMRV vaccine lineup is also licensed for IM use in the European Union.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20349

Which geographic areas are influencing the growth of the proquad market?

North America was the largest region in the proquad market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proquad market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Autoimmune Disease Diagnosis Global Market Report 2025

https://thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Hepatitis B Virus (HBV) Global Market Report 2025

https://thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Global Drug Delivery Devices Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/drug-delivery-devices-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: